Evolus (EOLS) Short Interest Ratio & Short Volume → 30-day gains? (From TradeSmith) (Ad) Free EOLS Stock Alerts $13.39 +0.09 (+0.68%) (As of 05/6/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Evolus Short Interest DataCurrent Short Volume4,640,000 sharesPrevious Short Volume4,650,000 sharesChange Vs. Previous Month-0.22%Dollar Volume Sold Short$55.17 millionShort Interest Ratio / Days to Cover8.1Last Record DateApril 15, 2024Outstanding Shares62,590,000 sharesFloat Size48,470,000 sharesShort Percent of Float9.57%Today's Trading Volume457,225 sharesAverage Trading Volume626,716 sharesToday's Volume Vs. Average73% Short Selling Evolus ? Sign up to receive the latest short interest report for Evolus and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEOLS Short Interest Over TimeEOLS Days to Cover Over TimeEOLS Percentage of Float Shorted Over Time Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit Evolus Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20244,640,000 shares $55.17 million -0.2%9.6%8.1 $11.89 3/31/20244,650,000 shares $65.10 million -6.6%9.8%7.1 $14.00 3/15/20244,980,000 shares $69.22 million +0.4%10.5%7.7 $13.90 2/29/20244,960,000 shares $73.56 million +1.2%11.3%8.2 $14.83 2/15/20244,900,000 shares $67.47 million +2.9%11.1%8.1 $13.77 1/31/20244,760,000 shares $60.40 million +17.2%10.8%6.6 $12.69 Get the Latest News and Ratings for EOLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,060,000 shares $42.83 million -7.3%9.2%5.4 $10.55 12/31/20234,380,000 shares $46.12 million -1.1%9.9%6.3 $10.53 12/15/20234,430,000 shares $43.86 million -9.0%10.0%6.5 $9.90 11/30/20234,870,000 shares $46.12 million -25.4%11.0%7.3 $9.47 11/15/20236,530,000 shares $58.18 million +60.8%14.8%10.2 $8.91 10/31/20234,060,000 shares $30.86 million +4.4%9.2%7.1 $7.60 10/15/20233,890,000 shares $31.66 million +1.3%8.8%6.5 $8.14 9/30/20233,840,000 shares $35.10 million +7.9%9.1%7.1 $9.14 9/15/20233,560,000 shares $33.61 million +5.3%8.4%6.2 $9.44 8/31/20233,380,000 shares $33.43 million -0.6%8.0%5.1 $9.89 8/15/20233,400,000 shares $34.68 million -21.7%8.1%5 $10.20 7/31/20234,340,000 shares $43.49 million -1.6%10.1%6.2 $10.02 7/15/20234,410,000 shares $32.63 million +24.6%10.3%7.8 $7.40 6/30/20233,540,000 shares $25.74 million +17.6%8.3%6.1 $7.27 6/15/20233,010,000 shares $23.15 million +7.1%7.1%5.6 $7.69 5/31/20232,810,000 shares $25.43 million -0.4%6.6%5.6 $9.05 5/15/20232,820,000 shares $29.10 million +2.2%6.6%6.4 $10.32 4/30/20232,760,000 shares $24.12 million +9.5%6.6%5.4 $8.74 4/15/20232,520,000 shares $21.14 million +4.1%6.0%4.8 $8.39 3/31/20232,420,000 shares $20.47 million +10.5%5.8%4.6 $8.46 3/15/20232,190,000 shares $18.75 million -0.9%5.2%4.1 $8.56 2/28/20232,210,000 shares $20.04 million -6.4%5.4%4.2 $9.07 2/15/20232,360,000 shares $22.11 million +6.3%5.8%4.5 $9.37 1/31/20232,220,000 shares $23.07 million -14.3%6.1%4.6 $10.39 1/15/20232,590,000 shares $22.40 million +0.4%7.0%6.2 $8.65 12/30/20222,580,000 shares $19.38 million +33.7%7.0%6.7 $7.51 12/15/20221,930,000 shares $13.55 million -15.4%5.2%4.8 $7.02 11/30/20222,280,000 shares $16.51 million -2.6%6.2%5.7 $7.24 11/15/20222,340,000 shares $17.64 million -8.2%6.3%5.7 $7.54 10/31/20222,550,000 shares $21.83 million -5.2%6.9%5.7 $8.56 10/15/20222,690,000 shares $22.41 million +24.0%7.3%5.2 $8.33 9/30/20222,170,000 shares $17.47 million +11.3%5.9%4.1 $8.05 9/15/20221,950,000 shares $19.81 million -5.3%5.3%3.9 $10.16 8/31/20222,060,000 shares $19.80 million -3.7%5.7%3.9 $9.6130-day gains? (Ad)Most Americans have zero idea how advanced A.I. has gotten. To them, it’s still a simple little chatbot that works like a really good version of Google. What they don’t realize is that it is becoming the go-to competitive advantage for people who are serious about their financial well-being. Whether it’s improving productivity at work, replacing employees in their business… or outperforming in the markets. A.I. grants the competitive advantage necessary to get ahead in this economy. It’s become the digital edge that can deliver solid returns… consistently.They can be viewed right here. EOLS Short Interest - Frequently Asked Questions What is Evolus' current short interest? Short interest is the volume of Evolus shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 4,640,000 shares of EOLS short. 9.57% of Evolus' shares are currently sold short. Learn More on Evolus' current short interest. What is a good short interest ratio for Evolus? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EOLS shares currently have a short interest ratio of 8.0. Learn More on Evolus's short interest ratio. Which institutional investors are shorting Evolus? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Evolus: Concourse Financial Group Securities Inc., Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Evolus? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.57% of Evolus' floating shares are currently sold short. Is Evolus' short interest increasing or decreasing? Evolus saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 4,640,000 shares, a drop of 0.2% from the previous total of 4,650,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Evolus' float size? Evolus currently has issued a total of 62,590,000 shares. Some of Evolus' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Evolus currently has a public float of 48,470,000 shares. How does Evolus' short interest compare to its competitors? 9.57% of Evolus' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Evolus: Phibro Animal Health Co. (3.10%), Arcturus Therapeutics Holdings Inc. (18.77%), Disc Medicine, Inc. (14.90%), Y-mAbs Therapeutics, Inc. (7.04%), AnaptysBio, Inc. (18.01%), Bicycle Therapeutics plc (9.85%), Silence Therapeutics plc (0.49%), Nuvation Bio Inc. (2.37%), Pliant Therapeutics, Inc. (12.63%), Praxis Precision Medicines, Inc. (4.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Evolus stock? Short selling EOLS is an investing strategy that aims to generate trading profit from Evolus as its price is falling. EOLS shares are trading up $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Evolus? A short squeeze for Evolus occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EOLS, which in turn drives the price of the stock up even further. How often is Evolus' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EOLS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Phibro Animal Health Short Squeeze Arcturus Therapeutics Short Squeeze Disc Medicine Short Squeeze Y-mAbs Therapeutics Short Squeeze AnaptysBio Short Squeeze Bicycle Therapeutics Short Squeeze Silence Therapeutics Short Squeeze Nuvation Bio Short Squeeze Pliant Therapeutics Short Squeeze Praxis Precision Medicines Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EOLS) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersMysterious Gold Leverage Just AnnouncedStansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceIs Tesla going out of business?DTITech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media